I can very much relate to the frustration with the amount of time involved with seeing any return on my investment in Advaxis. This was my first, and will be my last investment into the biotech market. My knowledge of patent law is nil. However I assume that most patents in the US have a 20 year span, and I also assume that having Orphan Status grants some sort of market exclusivity: https://en.wikipedia.org/wiki/Term_of_patent_in_the_United_States http://pharmaceuticalcommerce.com/opinion/common-misconceptions-about-the-orphan-drug-designation/ Years ago someone once speculated on the Yahoo MB that our base vaccines could possibly be able to be reproduced by other entities if they were somehow able to allow the attenuated LM to grow and multiply; however I have no idea if this is possible? IP is a key thing; and I personally do not have a lot of confidence in IP protection outside of the US and EU, again this is pure speculation on my part and I do not have any factual basis for this assumption. The good news that I perceive is that our platform appears to be able to adapt and change; and could possibly be the vehicle for endless applications in immunotherapy.
News 
Market Data 
Discover 
AI
